Tonix Pharmaceuticals has pushed back the planned start of a Phase 2 clinical trial testing its oxytocin-containing TNX-2900 nasal spray in children and adolescents with Prader-Willi syndrome (PWS). Tonix had expected the U.S.-based study, which has been cleared by the U.S. Food and Drug Administration (FDA), to start…